David Sherr’s team investigated AhR agonists and antagonists in a direct comparison and concluded that the sustained activation of AhR drives the later, more lethal stages of some cancers, but that AhR agonists under some circumstances can counteract tumor development and may also serve as cancer therapeutics (Narasimhan et al., 2018). The gene discussed is AHR; the disease is cancer.